Leonard A Oppenheim
CIK 1307647 · last filed 2022-01-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NEXM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
2479 E. BAYSHORE ROAD, SUITE 195
PALO ALTO, CA 94303
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XTI Aerospace, Inc. (INPX) Delisted | Director | 0 | $5.27 | $0 | $0 | 7 | 2022-01-10 |
| XTI Aerospace, Inc. (SYRX) Delisted | Director | 6,812 | — | — | $0 | 10 | 2017-02-07 |
| SEELOS THERAPEUTICS, INC. (APRI) Delisted | Director | 68 | — | — | -$37.9K | 9 | 2014-02-10 |
| NEXM | Director | 16,104 | $1.64 | $26.4K | -$63.4K | 15 | 2010-04-01 |
Recent Filings · Page 3 of 5
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-01-04 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | +2,784 | $14.3K | EDGAR |
| 2011-10-04 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | +2,784 | $10.0K | EDGAR |
| 2011-07-05 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | +2,784 | $9.9K | EDGAR |
| 2011-05-18 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | +2,784 | $9.9K | EDGAR |
| 2011-01-07 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | +2,179 | $10.0K | EDGAR |
| 2010-10-04 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | +2,179 | $10.0K | EDGAR |
| 2010-07-02 | — | Grant (A) | +2,179 | $10.0K | |
| 2010-04-01 | NEXM | Grant (A) | +32,680 | $10.0K | EDGAR |
| 2009-12-18 | NEXM | Sell (S) | −150,707 | -$63.4K | EDGAR |
| 2009-10-19 | NEXM | Grant (A) | +10,708 | $15.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.